Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
The advent of biologic agents has provided a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders. Such biologic agents have been relatively well tolerated with fewer adverse events reported as compared with many other chemotherapeutic agents. Rituximab is a monoclonal antibody to the B-cell marker CD20 and is a common biologic agent widely used for the treatment of B-cell lymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory to conventional treatment, including rheumatoid arthritis and some vasculitides. However, through randomized controlled trials and post-marketing surveillance, an increasing number of serious adverse events are being associated with the use of rituximab, often leading to or complicating an intensive care unit admission. The purpose of this review is to focus on the severe complications that are associated with the use of rituximab and that require critical care. Management and prevention strategies for the most common complications along with some examples of its uses within the critical care setting are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866 · cited 1×
“Patients have also presented with JC virus reactivation, leading to pro gressive multifocal leukoencephalopathy [68].”
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823 · cited 3×
“Th e most common reactions (incidence of at least 25%) in patients receiving rituximab monotherapy were infusion reactions and neutropenia [3,9].”
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Cairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570 · cited 7×
“ATLS results from ‘the rapid destruction of malignant cells, which abruptly release intracellular ions, proteins and metabolites into the extra-cellular space’ [55].”
InfluentialGhielmini, M. (2004) · Blood · doi:10.1182/blood-2003-10-3411 · Cited by 570 · cited 2×
“One case of fatal myo carditis was documented on autopsy in a study of 202 patients treated with rituximab for follicular lymphoma [60].”
Stasi, R., Pagano, A., Stipa, E., & Amadori, S. (2001) · Blood · doi:10.1182/blood.v98.4.952 · Cited by 568
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Rituximab: Mechanism of action and resistance
Maloney, D. G., Smith, B., & Rose, A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30156 · Cited by 375
Economics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348 · cited 1×
“Introduction Yearly sales of rituximab in the US already exceed $2 billion, attesting to its increasing US Food and Drug Administration (FDA)-approved and off -label use in multiple clinical settings such as B-cell lymphoma, lympho proliferative disorders, and refractory infl ammatory conditions, including rheumatoid…”
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., & Greco, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.191 · Cited by 330
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
Rituximab-related viral infections in lymphoma patients
Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D. S., Dizdar, O., Altundag, K., & Barista, I. (2007) · Leukemia & Lymphoma · doi:10.1080/10428190701411441 · Cited by 253
Aggarwal, S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3186 · Cited by 242 · cited 1×
“Introduction Yearly sales of rituximab in the US already exceed $2 billion, attesting to its increasing US Food and Drug Administration (FDA)-approved and off -label use in multiple clinical settings such as B-cell lymphoma, lympho proliferative disorders, and refractory infl ammatory conditions, including rheumatoid…”
Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*
Darmon, M., Thiery, G., Ciroldi, M., de Miranda, S., Galicier, L., Raffoux, E., Le Gall, J.-R., Schlemmer, B., & Azoulay, É. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000181728.13354.0a · Cited by 190
Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Léger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi320 · Cited by 166
Buske, C., Hoster, E., Dreyling, M. H., Eimermacher, H., Wandt, H., Metzner, B., Fuchs, R. J., Bittenbring, J. T., Wormann, B. J., Hohloch, K., et al. (2008) · Leukemia · doi:10.1038/leu.2008.261 · Cited by 166
Ostensen, M., Lockshin, M., Doria, A., Valesini, G., Meroni, P., Gordon, C., Brucato, A., & Tincani, A. (2008) · Rheumatology · doi:10.1093/rheumatology/ken168 · Cited by 165 · cited 2×
“Although rituximab is secreted into the breast milk of lactating monkeys, there are insufficient data for or against its use during breast feeding in humans [30].”
Taylor, R. P., & Lindorfer, M. A. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0424 · Cited by 159
Schellongowski, P., Staudinger, T., Kundi, M., Laczika, K. F., Locker, G. J., Bojic, A., Robak, O., Fuhrmann, V., Jäger, U., Valent, P., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031583 · Cited by 151 · cited 1×
“Th e presenting complaint and requirement for ICU admission in these cases are unknown; however, de novo acute myeloid leukemia may be diagnosed in the ICU when patients who have a history of cancer or who recently received chemotherapy present with acute respiratory failure, severe infection, bleeding, or renal dysfu…”
Tydén, G., Genberg, H., Tollemar, J. G., Ekberg, H., Persson, N. H., Tufveson, G., Wadström, J., Gäbel, M., & Mjörnstedt, L. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a235fd · Cited by 140
Freedman, A. S., Neelapu, S. S., Nichols, C. R., Robertson, M. J., Djulbegović, B., Winter, J. N., Bender, J. F., Gold, D. P., Ghalie, R., Stewart, M. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8903 · Cited by 138
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
Keir, G. J., Maher, T. M., Hansell, D. M., Denton, C. P., Ong, V. H., Singh, S., Wells, A. U., & Renzoni, E. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00163911 · Cited by 138 · cited 1×
“tissue disease In a retrospective cohort study of patients with pro gressive interstitial lung disease (ILD) associated with connective tissue disease not responding to conventional immunosuppressive regimens, rituximab improved lung function in seven of eight patients [24].”
Clinical review: specific aspects of acute renal failure in cancer patients.
Darmon, M., Ciroldi, M., Thiéry, G., Schlemmer, B., & Azoulay, É. (2006) · Critical Care · doi:10.1186/cc4907 · Cited by 137
Markert, A., Thierry, V., Kleber, M., Behrens, M., & Engelhardt, M. M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23991 · Cited by 110
A review of rituximab in cutaneous medicine
Scheinfeld, N. S. (2006) · Dermatology Online Journal · doi:10.5070/d34ns1k655 · Cited by 57
Rituximab and Cytokine Release Syndrome
Kulkarni, H. S., & Kasi, P. M. (2012) · Case Reports in Oncology · doi:10.1159/000337577 · Cited by 55
Self-citationTreatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab
Cartin‐Ceba, R., Fervenza, F. C., & Specks, U. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d5730 · Cited by 55
Biehn, S. E., Kirk, D., Rivera, M. P., Martínez, A. E., Khandani, A. H., & Orlowski, R. Z. (2006) · Hematological Oncology · doi:10.1002/hon.799 · Cited by 53 · cited 3×
“Bronchiolitis obliterans present ing as cough, dyspnea, and pulmonary nodules has been described in patients receiving rituximab [62].”
Schwartzberg, L. S., Stepanski, E. J., Fortner, B. V., & Houts, A. C. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-007-0329-5 · Cited by 47
Rituximab-Induced Hypersensitivity Pneumonitis
Tonelli, A. R., Lottenberg, R., Allan, R. W., & Sriram, P. (2008) · Respiration · doi:10.1159/000163069 · Cited by 44
Schwartzberg, L. S., Stepanski, E. J., Walker, M. S., Mathias, S. D., Houts, A. C., & Fortner, B. V. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0474-5 · Cited by 38 · cited 2×
“Grade 3 and 4 (severe, life-threatening) infusion reactions resulted in signifi cantly higher infusion-associated human resource costs compared with when no infusion reactions occurred (median cost of $220 versus $120) [7].”
Seifert, G., Reindl, T., Lobitz, S., Seeger, K., & Henze, G. (2006) · PubMed · Cited by 26
Yang, B. Y., Lu, X.-C., Yu, R., Zhang, W.-Y., Zhu, H.-L., Chi, X.-H., Yuan, J., & Zhao, P. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318244db6f · Cited by 25
Off-Label Use of Rituximab in a Multipayer Insurance System
Allen, E. M. V., Miyake, T., Gunn, N., Behler, C. M., & Kohlwes, J. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2010.000042 · Cited by 23
Copelan, E. A., Pohlman, B. L., Rybicki, L. A., Kalaycio, M. E., Sobecks, R. M., Andresen, S., Dean, R. M., Koo, A. P., Chan, J., Sweetenham, J. W., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.306 · Cited by 16
Cited by
Muntyanu, A., Netchiporouk, E., Gerstein, W., Gniadecki, R., & Litvinov, I. V. (2021) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420943260 · Cited by 177
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Metadata
- Authors
- Kasi, P. M., Tawbi, H. A., Oddis, C. V., & Kulkarni, H. S.
- Venue
- Critical Care
- Published
- 2012
- Volume
- 16
- Issue
- 4
- Pages
- 231
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2020044267
- Cited by
- 194
- References
- 51
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.